ClinicalTrials.gov
public full text
Public Domain
DexmedetOmidine Complement Treats Chronic insOmnia and Improves Circadian Rhythm (DOCTOR)
It has been reported that dexmedetomidine, alpha-2 adrenoceptor agonist, can activate endogenous neural sleep pathways in the central nervous system. This randomised, double-blinded and controlled trial was designed to investigate whether dexmedetomidine can improve/treat chronic insomnia patients. Its effects on sleep quality and improvement, EEG and circadian rhythm, brain connectivity, cognition and biomarker changes are determined.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Sleep disorders in stroke rehabilitation: mechanisms, impacts, and multidisciplinary management - a narrative review.#1068728
- Combined Behavioral/Pharmacological Therapy for Insomnia#1095061
- Pharmacological and non-pharmacological methods of inducing wakefulness activate distinct neural populations in the mouse brain#156000
- Improving Sleep and Learning in Rehabilitation After Stroke, Part 2#982496
- The Effects of a Nutritional Supplement on Sleep Quality#856757
Record · ID 880682
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive